Eligibility and Enrollment for Hepatitis C-AIDS Drug Assistance Program

Eligibility
Eligibility will be restricted to those who meet the following qualifications:

- Age 18 or older
- Co-infected with chronic HCV genotype 1, 2, 3, 4 or 5 and HIV, with a certification from their medical provider indicating the client is a good candidate for HCV treatment
- Negative pregnancy test, if applicable
- Prescriber must be experienced in HCV care or treating in collaboration with a specialist in HCV care, agree to monitor patient during the treatment, and maintain an appropriate treatment plan
- Income-eligible for participation in the ADAP (income at or less than 200 percent of federal poverty level)
- Actively filling HIV medication prescriptions
- Review for other funding sources including Medicare, Medicaid, VA, Private Insurance, and Pharmaceutical company Patient Assistance Programs (PAP)
- The client’s medical provider is willing to share follow-up data and documentation on the enrolled patient at 12-week intervals

*Note: Genotype 5 Sovaldi, Ribavirin requires Peg Interferon not offered HCV DAA ADAP formulary

Eligibility will be denied or the client will be dis-enrolled for the following reasons:

- Patient has previously failed to complete therapy with DAA for HCV due to patient non-adherence to therapy due to substance abuse and required enrollment in treatment program has failed.
- Patient is non-adherent to therapy for more than 7 days
- Insufficient resources to procure DAA
- Exceptions will be considered for circumstances beyond the prescriber or patient’s control

Enrollment Process
Community education about the ADAP for HIV and HCV (ADAP-HCV) co-infected individuals will begin with the Administrative Agencies. The Administrative Agencies are regional agencies that administer HIV funds to local organizations offering care and supportive services. Through a series of webinars and emails, the Administrative Agencies and their funded community agencies will learn how to identify those clients who are appropriate for the pilot program. All ADAP-HCV pilot documents will be available online to facilitate program application. The THMP application, used for initial eligibility and recertification, will be revised to ask clients about their HCV status and if they wish to be considered for the ADAP-HCV program. This will allow for those clients currently on the ADAP program to receive HCV treatment. Clients considered for the program will receive a special Medical Certification Form (MCF) specific to HCV DAAs that they will need to fill out with their medical doctor (see attachment 1).
The THMP Eligibility Specialist will work with community agencies and the client to enroll each eligible client into the ADAP-HCV. The medical provider will be followed up with at 12 and 24 weeks to determine treatment effectiveness.

Effective November 1, 2017